Summary:
- Blueprint Medicines, a biopharmaceutical company, has provided its 2025 outlook and highlighted its strategy for the future.
- The company aims to expand its portfolio of targeted therapies, focusing on rare genetic diseases, cancer, and other areas of high unmet medical need.
- Blueprint Medicines plans to advance its pipeline of investigational medicines, including several late-stage programs, and continue to invest in its research and development capabilities.